- CITATIONS: 3
|Application ||IHC-P-Leica, WB, E|
|Other Accession||Q99P68, Q99P67, Q9BG79|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||24031 Da|
|Antigen Region||12-42 aa|
|Other Names||Sclerostin, SOST|
|Target/Specificity||This SOST antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 12-42 amino acids from the N-terminal region of human SOST.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||SOST Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.|
|Cellular Location||Secreted, extracellular space, extracellular matrix|
|Tissue Location||Widely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteoblasts differentiated for 21 days. Detected in the subendothelial layer of the aortic intima (at protein level).|
Provided below are standard protocols that you may find useful for product applications.
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.
Semenov,M.V., J. Biol. Chem. 281 (50), 38276-38284 (2006)
Ellies,D.L., J. Bone Miner. Res. 21 (11), 1738-1749 (2006)
Balemans,W., J Musculoskelet Neuronal Interact 6 (4), 355-356 (2006)
Gardner,J.C., J. Clin. Endocrinol. Metab. 90 (12), 6392-6395 (2005)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.